Tumor necrosis factor-α promoter polymorphism at position-308 predicts response to combination therapy in hepatitis C virus infection

被引：59

作者：

Dai, CY

Chuang, WL

Chang, WY

Chen, SC

Lee, LP

Hsieh, MY

Hou, NJ

Lin, ZY

Huang, JF

Hsieh, MY

Wang, LY

Yu, ML

机构：

[1] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan

[2] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Dept Internal Med, Kaohsiung 807, Taiwan

[3] Fooyin Univ Hosp, Dept Internal Med, Pingtung, Taiwan

来源：

JOURNAL OF INFECTIOUS DISEASES | 2006年 / 193卷 / 01期

关键词：

D O I：

10.1086/498244

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The G -> A transition in the tumor necrosis factor (TNF) a promoter region at position -308 (TNF308.2) and -238 (TNF238.2) were determined in 141 patients with chronic hepatitis C virus (HCV) infection. Patients received combination therapy with high-dose interferon (IFN)-alpha and ribavirin for 24 weeks. A total of 100 patients (70.9%) had a sustained virologic response (SVR) after treatment. The TNF308.2 allele was independently associated with an SVR, particularly in patients with HCV genotype 1b infection and > 200,000 IU of HCV RNA/mL in serum. In conclusion, the response to combination therapy with high-dose IFN-alpha and ribavirin may be associated, at least in part, with host genetic factors.

引用

页码：98 / 101

页数：4

共 15 条

[1]

DALFONSO S, 1994, IMMUNOGENETICS, V39, P150

[2]

Höhler T, 1998, J MED VIROL, V54, P173, DOI 10.1002/(SICI)1096-9071(199803)54:3<173::AID-JMV5>3.0.CO

[3]

2-2

[4] The-238 tumor necrosis factor-α promoter polymorphism is associated with decreased susceptibility to cancers [J].